The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors.
VEGFR-TKI
appetite
cancer-related anorexia-cachexia syndrome
gastrointestinal symptoms
malnutrition
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
04
2023
accepted:
07
09
2023
medline:
29
9
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
Cancer-related anorexia is a common complication and frequently occurs in cancer patients treated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs). Anorexia contributes to malnutrition, body weight loss, and cachexia in affected patients. Furthermore, patients who experience anorexia have worse outcomes than those who maintain their appetite, highlighting the importance of managing anorexia and related symptoms. However, as the causes of anorexia are both diverse and interconnected, there have been challenges in evaluating and implementing effective interventions. In this review, we described the contributing factors to cancer-related anorexia and reviewed recent literature for the frequency of anorexia symptoms in patients treated with VEGFR-TKIs. Additionally, we evaluated the evidence for current interventions and the potential benefits of multimodal and multidisciplinary approaches to care. The frequency of anorexia symptoms in patients who received VEGFR-TKIs ranged from 14%-58% for all-grade anorexia and 0%-6% for grade 3 or 4 anorexia. While many of the interventions for cancer-related anorexia have minimal benefit or adverse events, recent advances in our understanding of cancer-related anorexia suggest that multimodal therapy with multidisciplinary care is a promising avenue of investigation. Several studies currently underway are anticipated to further assess the effectiveness of multimodal approaches.
Identifiants
pubmed: 37771675
doi: 10.2147/CMAR.S417238
pii: 417238
pmc: PMC10522463
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1033-1046Informations de copyright
© 2023 Takahashi et al.
Déclaration de conflit d'intérêts
Although authors received payment for advisory board services, this present manuscript was prepared independently with funding for medical writing only. Shunji Takahashi has received medical writing support from Eisai Co., Ltd.; grants or contracts from MSD K.K., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., AstraZeneca K.K., Bristol-Myers Squibb K.K., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Novartis Pharma K.K., Taiho Pharmaceutical Co., Ltd., and Daiichi Sankyo, Co., Ltd.; and payments or honoraria from Eisai Co., Ltd., Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., MSD K.K., Taiho Pharmaceutical Co., Ltd., Bayer Ltd., and Bristol-Myers Squibb K.K. Koji Matsumoto has received medical writing support from Eisai Co., Ltd.; payments or honoraria from Eisai Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Bristol-Myers Squibb K.K., ACTmed Co., Ltd., Bayer Yakuhin Ltd., Ono Pharmaceutical Co., Ltd., and Kaken Pharmaceutical Co., Ltd.; and participated on a data safety monitoring board or advisory board for Eisai Co., Ltd, AstraZeneca K.K., MSD K.K., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., and Genmab K.K. Kojiro Ohba, Yasuhiro Nakano, Yasushi Miyazawa, and Takumi Kawaguchi have received payment or honoraria from Eisai Co., Ltd., and medical writing support for the present manuscript. Yasushi Miyazawa has received consulting fees from AIM Services Co., Ltd., Forico Foods Co., Ltd., and TOP Corporation; payment or honoraria from Nestlé Health Science Co., Ltd. and Otsuka Pharmaceutical Factory, Inc.; and has a leadership or fiduciary role in The Japan Association for Nutritional Management Practice. Takumi Kawaguchi has received consulting fees from ASKA Pharmaceutical Co., Ltd., Kowa Co., Ltd., and Taisho Pharmaceutical Co., Ltd.; received payment or honoraria from ASKA Pharmaceutical Co., Ltd., AstraZeneca K.K., AbbVie GK., Chugai Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Gilead Sciences, Inc., Janssen Pharmaceutical K.K., KM Biologics, Kowa Company, Ltd., Merck & Co., Inc., Miyarisan Pharmaceutical Co., Ltd., Nobelpharma Co., Ltd., Novartis AG., Otsuka Pharmaceutical Factory, Inc., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., SMC Laboratories, Inc., and Taisho Pharmaceutical Co., Ltd.; and has received medical writing support from Eisai Co., Ltd. The authors report no other conflicts of interest in this work.
Références
Front Nutr. 2020 Apr 17;7:49
pubmed: 32363198
J Cachexia Sarcopenia Muscle. 2015 Mar;6(1):99-111
pubmed: 26136417
BMC Palliat Care. 2013 Oct 29;12(1):38
pubmed: 24165041
Asia Pac J Oncol Nurs. 2022 Apr 28;9(9):100075
pubmed: 35669286
J Gastroenterol. 2013 May;48(5):574-94
pubmed: 23512346
Peptides. 2016 Mar;77:60-6
pubmed: 26158772
J Clin Oncol. 2022 Aug 1;40(22):2491-2507
pubmed: 35576506
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Support Care Cancer. 2017 May;25(5):1651-1659
pubmed: 28074289
Am Soc Clin Oncol Educ Book. 2015;:e229-37
pubmed: 25993178
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
J Hematol Oncol. 2019 Mar 12;12(1):27
pubmed: 30866992
Lancet Oncol. 2015 Nov;16(15):1473-1482
pubmed: 26482279
Eur J Cancer. 2021 Mar;145:245-254
pubmed: 33419647
Mol Clin Oncol. 2020 Oct;13(4):29
pubmed: 32765876
N Engl J Med. 2011 Feb 10;364(6):501-13
pubmed: 21306237
Drugs. 2001;61(4):499-514
pubmed: 11324680
Clin Nutr. 2021 Feb;40(2):525-533
pubmed: 32600857
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
Support Care Cancer. 2019 Jul;27(7):2371-2384
pubmed: 30944994
JAMA Oncol. 2018 Oct 1;4(10):1375-1381
pubmed: 30027204
Support Care Cancer. 2020 Jul;28(7):3041-3049
pubmed: 31578643
J Pain Palliat Care Pharmacother. 2022 Jun;36(2):117-131
pubmed: 35758863
Front Nutr. 2022 Jan 31;8:797513
pubmed: 35174197
J Exp Clin Cancer Res. 2020 Oct 7;39(1):210
pubmed: 33028357
Clin Ther. 2017 Nov;39(11):2216-2229
pubmed: 29055500
Eur J Clin Pharmacol. 2017 Oct;73(10):1209-1217
pubmed: 28710508
Cancer Treat Res Commun. 2021;27:100336
pubmed: 33607591
Biomed Res Int. 2018 May 24;2018:5035217
pubmed: 29992147
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD004310
pubmed: 23543530
J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):778-788
pubmed: 28614627
Cancer Manag Res. 2020 Jul 09;12:5597-5605
pubmed: 32753972
Lancet Oncol. 2013 Dec;14(13):1287-94
pubmed: 24206640
Expert Rev Anticancer Ther. 2022 Jul;22(7):737-749
pubmed: 35699257
Int Immunopharmacol. 2021 Oct;99:108031
pubmed: 34358857
Ann Oncol. 2018 May 1;29(5):1141-1153
pubmed: 29788170
Support Care Cancer. 2021 Aug;29(8):4885-4892
pubmed: 33598734
Lancet. 2006 Oct 14;368(9544):1329-38
pubmed: 17046465
Support Care Cancer. 2010 Feb;18(2):265-72
pubmed: 19937260
Appetite. 2017 Jul 1;114:23-27
pubmed: 28315777
J Clin Endocrinol Metab. 2005 May;90(5):2920-6
pubmed: 15713718
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Lancet Oncol. 2009 Sep;10(9):865-71
pubmed: 19695956
Antibiotics (Basel). 2021 Jul 06;10(7):
pubmed: 34356743
Lung Cancer. 2017 Oct;112:25-34
pubmed: 29191597
Clin Nutr. 2017 Oct;36(5):1187-1196
pubmed: 28689670
BMC Cancer. 2019 May 31;19(1):528
pubmed: 31151425
Nutrients. 2022 Oct 07;14(19):
pubmed: 36235818
BMC Cancer. 2014 Nov 16;14:828
pubmed: 25400234
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
J Clin Oncol. 2013 Oct 10;31(29):3639-46
pubmed: 24002501
Int J Mol Sci. 2020 Mar 27;21(7):
pubmed: 32230855
J Clin Med. 2020 Jul 30;9(8):
pubmed: 32751451
Clin Nutr. 2008 Dec;27(6):793-9
pubmed: 18718696
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Ann Palliat Med. 2019 Jan;8(1):50-58
pubmed: 29860861
Med Sci (Basel). 2020 Oct 09;8(4):
pubmed: 33050250
J Pain Symptom Manage. 2021 Sep;62(3):e164-e176
pubmed: 33652095
ESMO Open. 2021 Jun;6(3):100092
pubmed: 34144781
Asia Pac J Oncol Nurs. 2021 Aug 27;8(5):487-497
pubmed: 34527778
Cell Physiol Biochem. 2018;48(5):2172-2188
pubmed: 30110683
BMJ Support Palliat Care. 2018 Sep;8(3):258-265
pubmed: 29440149
BMJ Support Palliat Care. 2019 Mar;9(1):67-74
pubmed: 26700484
Int J Mol Sci. 2021 Aug 06;22(16):
pubmed: 34445197
Support Care Cancer. 2009 Dec;17(12):1531-41
pubmed: 19350287
Int J Mol Sci. 2018 Oct 21;19(10):
pubmed: 30347885
J Cachexia Sarcopenia Muscle. 2021 Feb;12(1):14-16
pubmed: 33382205
J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):619-635
pubmed: 32142217
Semin Oncol Nurs. 2022 Feb;38(1):151254
pubmed: 35379449
Anticancer Res. 2009 Oct;29(10):3949-52
pubmed: 19846934
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922780
Nutr Cancer. 2015;67(1):12-26
pubmed: 25513730
Biochem Biophys Res Commun. 2009 Aug 14;386(1):212-6
pubmed: 19523445
Asia Pac J Oncol Nurs. 2021 Aug 27;8(5):498-507
pubmed: 34527779
Nutr Cancer. 2022;74(2):482-495
pubmed: 33605813
Biochem J. 2021 May 14;478(9):1663-1688
pubmed: 33970218
Support Care Cancer. 2020 Oct;28(10):4575-4583
pubmed: 32451701
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Front Nutr. 2022 Jan 03;8:761267
pubmed: 35047540
Lancet. 2014 Jul 26;384(9940):319-28
pubmed: 24768112
Lancet Oncol. 2016 Apr;17(4):519-531
pubmed: 26906526
Oncoimmunology. 2020 Oct 5;9(1):1824645
pubmed: 33101774
Psychoneuroendocrinology. 2010 Sep;35(8):1178-86
pubmed: 20188481
J Clin Oncol. 2005 Sep 1;23(25):6240-8
pubmed: 16135490
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
Clin Nutr. 2017 Feb;36(1):11-48
pubmed: 27637832
Nutrients. 2021 Aug 24;13(9):
pubmed: 34578798
BMJ Support Palliat Care. 2017 Dec;7(4):441-449
pubmed: 28847854
Cancer. 2019 Dec 1;125(23):4294-4302
pubmed: 31415709
J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):287-302
pubmed: 26675762
Lancet. 2013 Jan 26;381(9863):295-302
pubmed: 23177515
J Clin Oncol. 2023 May 10;41(14):2617-2627
pubmed: 36977285
Curr Opin Clin Nutr Metab Care. 2017 Sep;20(5):340-345
pubmed: 28598896
Int J Cancer. 2014 Aug 15;135(4):763-73
pubmed: 24127298
Oncol Nurs Forum. 2008 Sep;35(5):802-7
pubmed: 18765326
Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1000-8
pubmed: 18713954
Clin Nutr. 2018 Aug;37(4):1202-1209
pubmed: 28651827
J Pain Symptom Manage. 2006 Oct;32(4):322-31
pubmed: 17000349
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32244867
Ann Oncol. 2017 Aug 01;28(8):1949-1956
pubmed: 28472437
J Hum Nutr Diet. 2021 Feb;34(1):243-254
pubmed: 33038282
Cancer Lett. 2022 Feb 1;526:193-204
pubmed: 34843864
Int J Mol Sci. 2019 Dec 12;20(24):
pubmed: 31842339
J Clin Oncol. 2020 Jul 20;38(21):2438-2453
pubmed: 32432946
J Am Dent Assoc. 2018 Apr;149(4):291-298
pubmed: 29439772
J Cancer Res Ther. 2020 Jul-Sep;16(4):855-859
pubmed: 32930130
N Engl J Med. 2007 Jan 11;356(2):125-34
pubmed: 17215530
Nutrients. 2022 Jan 14;14(2):
pubmed: 35057531
Cancer. 2018 Feb 1;124(3):606-616
pubmed: 29205286
Nat Rev Endocrinol. 2018 Dec;15(1):9-20
pubmed: 30464312
Medicina (Kaunas). 2022 Jul 21;58(7):
pubmed: 35888685
Support Care Cancer. 2022 Jan;30(1):497-509
pubmed: 34331589
Palliat Med. 2002 Nov;16(6):499-506
pubmed: 12465697
Cochrane Database Syst Rev. 2021 Mar 18;3:CD010804
pubmed: 33735441
J Clin Oncol. 2021 Mar 1;39(7):748-756
pubmed: 33417481
J Clin Oncol. 2009 Aug 1;27(22):3584-90
pubmed: 19487381
JAMA Oncol. 2016 Sep 1;2(9):1170-6
pubmed: 27243607